A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 5, 1999, Pages 372-380

  Rinaldi, David A ^a,e   Kuhn, John G ^c   Burris, Howard A ^a   Dorr, F Andrew ^d   Rodriguez, Gladys ^b   Eckhardt, S Gail ^b   Jones, Suzanne ^b   Woodworth, James R ^d   Baker, Sharyn ^b   Langley, Connie ^b   Mascorro, David ^c   Abrahams, Trent ^d   Von Hoff, Daniel D ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b CTRC Institute for Drug Development   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e NONE   (United States)

Author keywords

Antifolate; LY231514; MTA; Multitargeted

Indexed keywords

FOLIC ACID ANTAGONIST; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENE TARGETING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COLORECTAL NEOPLASMS; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASMS; PANCREATIC NEOPLASMS; REGRESSION ANALYSIS; THROMBOCYTOPENIA;

EID: 0032859301     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050992     Document Type: Article

References (19)

1. 1. Thymidylate Synthase Inhibitor LY231514 (1994) Clinical Investigation Brochure. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis
2. 2. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123
3. 3. Grindey GB, Shih C, Barnett CJ, Pearce HL, Engelhardt JA, Todd GC, Rinzel SM, Worzalla JF, Gosseu LS, Everson TP (1992) LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 33: 411
4. 4. Von Hoff DD (1988) Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development. Cancer Metastasis Rev 7: 357-371
5. 5. Reference deleted
6. 6. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, Clark G, Faries D, Lu P, Von Hoff DD (1995) Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, utilizing the modified continual reassessment method for dose escalation. J Clin Oncol 13: 2842-2850
7. 7. McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T, McCarthy S, Bailey NP, Siddiqui N, Lind MJ, Calvert AH, Twelves CJ, Cassidy J, Kaye SB (1996) Phase 1 and pharmacokinetic study of LY231514, the multi-targeted antifolate. Ann Oncol 7 [Suppl 5]: 608P
8. 8. McDonald AC, Vasey PA, Walling J, Woodworth JR, Abrahams T, Bailey NP, Siddiqui N, Lind MJ, Cassidy J, Twelves CJ (1998) Phase 1 and pharmacokinetic study of LY231514, the multi-targeted antifolate, administered by daily x5, q21 schedule. Clin Cancer Res 4: 605-610
9. 9. Faries D (1994) Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 4: 147-164
10. 10. Liegler DG, Henderson ES, Hahn MA (1969) The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 10: 849-857
11. 11. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance using serum creatine. Nephron 16: 31
12. 12. Lalonde RL (1992) Pharmacodynamics. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics: principles of therapeutic drug monitoring. Applied Therapeutics, Vancouver, WA, pp 4-1 to 4-33
13. 13. Grem JL (1990) Fluorinated pyrimidines. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. JB Lippincott Co., Philadelphia, pp 180-224
14. 14. Schilsky RL (1992) Antimetabolites. In: Perry MC (ed) The chemotherapy source book. Williams and Wilkins, Baltimore, pp 301-315
15. 15. Touroutoglou N, Pazdur R (1996) Thymidylate synthase inhibitors. Clin Cancer Res 2: 227-243
16. 16. Laohavinij S, Wedge SR, Lind MJ, Bailey N, Humphreys A, Proctor M, Chapman F, Simmons D, Oakley A, Robson L, Gumbrell L, Taylor GA, Thomas HD, Boddy AV, Newell DR, Calvert AH (1996) A phase I clinical study of the antipurine antifolate Lometrexol (DDATHF) given with oral folic acid. Invest New Drugs 14: 325-335
17. 17. Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45: 925-937
18. 18. Geller NL (1990) Design of phase I and II trials in cancer. Drug Information J 24: 341-349
19. 19. O'Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase I cinical trials in cancer. Biometrics 46: 33-48